Treatment Effectiveness
User reported effectiveness ratings Celebrex for various conditions.
| Conditions | Major Improvement | Moderate Improvement | Much Worse | No Effect | Worse | Responses |
|---|---|---|---|---|---|---|
| Back Pain | 10% | 21% | 7% | 53% | 9% | 106 |
| Chronic Cerebrospinal Venous Insufficiency (CCSVI) | 0% | 100% | 0% | 0% | 0% | 1 |
| Fibromyalgia | 6% | 20% | 11% | 50% | 14% | 122 |
| Hemicrania Continua | 8% | 17% | 8% | 67% | 0% | 12 |
| Knee Pain | 14% | 38% | 10% | 34% | 3% | 29 |
| Osteoarthritis | 24% | 38% | 0% | 33% | 5% | 21 |
| Palindromic Rheumatism | 21% | 14% | 7% | 36% | 21% | 14 |
| Rheumatoid Arthritis | 19% | 45% | 4% | 30% | 2% | 53 |
| Anxiety | 4% | 12% | 20% | 52% | 12% | 25 |
Side Effects
User-reported side effects of Celebrex
| Side Effect | Percent of Reports Celebrex |
|---|---|
| Diarrhea | 14% |
| Cold Symptoms | 12% |
| Confusion | 15% |
| Gas or Bloating | 20% |
| Sore Throat | 8% |
Outcomes
Below is the degree of change seen after Celebrex is higher than average.
|
|
Outcomes Label
Celebrex Info
| Property | Value |
|---|---|
| Variable Name | Celebrex |
| Aggregation Method | SUM |
| Analysis Performed At | 2020-04-06 |
| Duration of Action | 21 days |
| Filling Value | 0 |
| Minimum Allowed Value | 0 count |
| Number of Aggregate Predictors | 0 |
| Number of Aggregate Outcomes | 0 |
| Number of Measurements | 0 |
| Number of Measurements (including those generated by tagged, joined, or child variables) | 0 |
| Public | true |
| Onset Delay | 30 minutes |
| Unit | Count |
| User Variables | 1 |
| UPC | 885367139385 |
| Variable Category | Treatments |
| Variable ID | 92836 |